Caprelsa (vandetanib) is indicated for the treatment of symptomatic or progressive Medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease.
Alberta Health Services has put the listing on their Outpatient Cancer Drug Benefit Program website. https://www.albertahealthservices.ca/assets/programs/ps-1025651-drug-benefit-list.pdf
Other provinces are in negotiations for listings.